Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
Many healthcare providers regard testosterone cypionate and testosterone enanthate as interchangeable, but each has differences in their ingredients and duration of action. These differences influence ...
Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...
* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...
Testosterone injections are a treatment for sexual dysfunction in males and for low testosterone in either males or females. They can also be part of gender affirming care. Although testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results